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ej@pbrc.edu (JianAbstract Insulin resistance is a major risk factor for type 2 diabetes. AMP-activated protein
kinase (AMPK) is a drug target in the improvement of insulin sensitivity. Several insulin-sensitizing
medicines are able to activate AMPK through inhibition of mitochondrial functions. These drugs,
such as metformin and STZ, inhibit ATP synthesis in mitochondria to raise AMP/ATP ratio in the
process of AMPK activation. However, chemicals that activate AMPK directly or by activating its
upstream kinases have not been approved for treatment of type 2 diabetes in humans. In an early
study, we reported that berberine inhibited oxygen consumption in mitochondria, and increased
AMP/ATP ratio in cells. The observation suggests an indirect mechanism for AMPK activation by
berberine. Berberine stimulates glycolysis for ATP production that offsets the cell toxicity after
mitochondria inhibition. The study suggests that mitochondrial inhibition is an approach for
AMPK activation. In this review article, literature is critically reviewed to interpret the role of
mitochondria function in the mechanism of insulin resistance, which supports that mitochondria
inhibitors represent a new class of AMPK activator. The inhibitors are promising candidates for
insulin sensitizers. This review provides a guideline in search for small molecule AMPK activators
in the drug discovery for type 2 diabetes.
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Type 2 diabetes (T2D) is characterized by hyperglycemia
coupled with hyperinsulinemia. The pathogenesis of T2D is
insulin resistance, in which body has a low response to insulin
although insulin remains at the normal or even higher levels in
the blood. In compensation to insulin resistance, pancreatic
b cells produce more insulin leading to insulin elevation.
Long-term such compensation increases burden in b cells
and often contributes to b cell failure at the end, which is
responsible for hyperglycemia and diabetic complications in
the late stage. Correction of insulin resistance has been a
therapeutic approach in the treatment of type 2 diabetes.
However, the medicines are very limited in the treatment of
insulin resistance1. There is a strong demand for identiﬁcation
of new insulin sensitization drugs1.
Mechanism of insulin resistance is a focus in search for new
diabetes medicines. There are several hypotheses regarding the
cellular and molecular mechanisms of insulin resistance2,3
(Fig. 1). Those include mitochondrial dysfunction, endoplas-
mic reticulum (ER) stress, lipotoxicity, AMPK reduction,
insulin elevation, oxidative stress, inﬂammation and adipo-
nectin reduction. All of those mechanisms are proposed
according to observations in the study of obesity, which
represents energy surplus (fatty acids or glucose) in the body.
Therefore, obese subjects have a high risk of insulin resistance.
Fatty acids contain high density of energy and elevation of
fatty acid in blood is a major risk factor for insulin resistance.
In an early review, we proposed that fatty acids in combina-
tion with insulin is a major risk factor for insulin resistance in
obesity3. In this review, we will extend this view point with a
focus on mitochondrial function.
Mitochondrion is a subcellular organ where fatty acids and
glucose are used in the production of ATP through the
oxidative phosphorylation process. The mitochondrial dys-
function is a hypothesis for insulin resistance4. The hypothesis
suggests that when mitochondria cannot completely burn the
fatty acids, the intermediate product of triglyceride such as
diaglyceride (DAG) will accumulate in the cells to activate
protein kinase C (PKC). In turn, PKC will induce insulin
resistance by suppressing insulin signaling pathway through
phosphorylation of insulin receptor substrate 1 (IRS-1)5.
However, in two recent reviews, pharmacological and genetic
evidence consistently suggest that mitochondrial dysfunctionFigure 1 Mechanism of insulin resistance. There are several
hypotheses about insulin resistance. These include mitochondrial
dysfunction, endoplasmic reticulum (ER) stress, adiponectin
reduction, inﬂammation, lipotoxicity, AMPK inactivation, oxida-
tive stress, and insulin elevation.is not a cause of insulin resistance6,7. Instead, mitochondrial
dysfunction is a consequence of insulin resistance.2. Mitochondrial regulation
Mitochondria are the power-generating subcellular organ in
cells and are required for ATP production in most cell types
except red blood cells. The most important role of mitochon-
dria is to produce ATP through oxidation of carbohydrate,
fatty acids and amino acids. The key mitochondria enzymes
include those such as pyruvate dehydrogenase, NADH dehy-
drogenase (Complex I), succinate dehydrogenase (Complex
II), cytochrome bc1 (Complex III), and cytochrome c oxidase
(Complex IV). In glucose catabolism, glucose is ﬁrst converted
into pyruvate through glycolysis in the cytoplasm. Pyruvate is
converted into acetyl-CoA in mitochondria by pyruvate
dehydrogenase, and then sent into TCA cycle to generate
ATP, CO2 and H2O. This process is dependent on oxygen, and
the activity is inhibited by hypoxia. In the absence of oxygen,
pyruvate cannot be used in ATP production in mitochondria,
but is converted into lactic acid in the cytoplasm in glycolysis
(Fig. 2). In this condition, each molecule of glucose can only
yield 2 molecules of ATP in net. In terms of fatty acid
catabolism, long chain fatty acids are broken down into
acetyl-CoA in mitochondria through b-oxidation, and acetyl-
CoA is then used for ATP production in TCA cycle (Fig. 2).
In hypoxia, TCA cycle is inhibited and thus, fatty acids cannot
be used in ATP production. Fatty acid catabolism is com-
pletely dependent on oxygen supply.
Mitochondrial function is regulated by several hormones and
substrates. In the hormones, insulin regulates mitochondrialFigure 2 Glucose and fatty acids catabolism in cells. Glucose
breaks down into pyruvate in the process of glycolysis. In the
hypoxia condition, pyruvate becomes lactic acid in the cytoplasm
and released out of cells. In the presence of oxygen, pyruvate is
converted into acetyl-CoA by PDH in the mitochondria, and then
used in TAC cycle for ATP production. The byproducts are water
and carbon dioxide. Fatty acids breaks down into acetyl-CoA
through b-oxidation in mitochondria, and then used in ATP
production through TCA cycle. In hypoxia condition, fatty acid
cannot be used in ATP production.
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mechanism includes insulin-induced gene expression and mito-
chondrial protein modiﬁcation by phosphorylation. Indirectly,
insulin increases substrate (glucose and fatty acid) supply to
mitochondria through stimulation of the transporter activities.
Glucose transporter 4 (GLUT4) and fatty acid transport protein
(FATP) are activated by insulin leading to enhanced uptake of
the substrates by cells. The gene expression, protein modiﬁcation
and substrate supply all promote mitochondrial function in ATP
production. In obesity, glucose, fatty acids and insulin are all
elevated in the blood. These factors promote mitochondrial
function and contribute to the pathogenesis of insulin resistance.
The mitochondria activation provides a mechanism for insulin
resistance in the presence of insulin and fatty acids3.
Mitochondria function is determined by mitochondria number,
size and quality. Those are controlled by mitochondrial biogenesis
and mitochondria autophagy. The biogenesis is determined by
gene expression and PGC-1a is a primary activator of the gene
expression. Mitochondrial biogenesis is regulated by multiple
factors. Insulin stimulates mitochondrial functions at multiple
steps including oxidative phosphorylation, gene transcription and
protein expression8. Mitochondrial recycle is regulated by autop-
hagy, which removes damaged mitochondria from cells and uses
them in energy production through recycling membrane lipids. In
addition, mitochondrial function is also regulated by calcium
homeostasis, reactive oxygen species (ROS), apoptosis and
thermogenesis. These factors are inﬂuenced by substrates, nitric
oxide, hypoxia, and hormones.3. Mitochondrial dysfunction and insulin resistance
Mitochondrial dysfunction was ﬁrst proposed as a mechanism of
insulin resistance by Dr. Shulman’s group4. This hypothesis is
supported by evidence in human and in animal. ADP is a
substrate in the synthesis of ATP, and is able to stimulate
mitochondria to produce ATP. This ADP activity is reduced in
type 2 diabetes patients with obesity9. In animal studies,
mitochondrial dysfunction is associated with insulin resistance10.
All parameters of mitochondria functions are decreased in the
adipose tissues of diabetic mice. Those include mitochondria
number, mitochondria DNA content, and respiratory enzymes,
oxidative phosphorylation (OXPHOS) and fatty acid b-oxida-
tion. Mitochondrial defects were induced in murine C2C12
myotube cells using the respiratory chain inhibitors. In this
cellular model, insulin actions such as insulin-stimulated glucose
uptake and AKT activation in the insulin signaling pathway are
decreased11. Inhibition of mitochondrial function by knocking
down mitochondrial transcription factor A (mtTFA) suppressed
insulin-stimulated glucose uptake. mtTFA is required for the
replication and transcription of mitochondria DNA. These
ﬁndings suggest that mitochondrial dysfunction from pharma-
cological treatment or genetic manipulation has close relation-
ship with insulin resistance in adipocytes. In diabetic subjects,
mitochondria number and mass are reduced in skeletal mus-
cle12,13. Several factors contribute to mitochondrial dysfunction.
3.1. Genetic factors
Mitochondrial biogenesis determines mitochondria mass and
number. The biogenesis is regulated by mitochondrial DNA
and genomic DNA. Mitochondrial DNA mutation presents inapproximately 2% of patients with type 2 diabetes mellitus
and in elderly individuals. In addition, a polymorphism of the
mitochondrial coding region of the ND1 gene (a subunit of
reduced NADH dehydrogenase) is associated with resting
metabolic rate (RMR) in a large group of non-diabetic Pima
Indians, a population with high risk of diabetes14. Mutation in
mitochondrial DNA that encodes tRNA impairs insulin
secretion in pancreatic b-cells15. Polymorphisms in the pro-
moter DNA of UCP2 gene are associated with decreased
incidence of obesity, reduced insulin secretion, and prevalence
of diabetes16,17. In addition, nuclear DNA may determine
mitochondrial function through encoding mitochondrial pro-
teins. These association studies indicate that mitochondrial or
nuclear DNA may inﬂuence mitochondrial function, and
mitochondria may inﬂuence glucose metabolism through
regulation of insulin sensitivity or insulin production. Nair
et al.18 suggests that race/ethnicity determines the role of
mitochondria in insulin resistance. In certain ethnic groups,
there is dissociation between mitochondrial dysfunction and
insulin resistance, and mitochondrial dysfunction cannot
account for insulin resistance.3.2. Oxidative stress
Mitochondrial function is dependent on oxygen during pro-
duction of ATP. Derivatives of oxygen such as O2
 are
generated during the process of ATP production. These
intermediate products of oxygen are reactive oxygen species
(ROS, a group of free radicals), and highly toxic for oxidation
of lipids, proteins and DNA. Mitochondria usually prevent
the toxicity by removal of those products through the anti-
oxidant system, which convert the free radicals into H2O and
CO2. If these intermediate products are not eliminated
immediately in mitochondria, they will induce oxidative stress
and damage protein, lipid and DNA functions through
chemical reactions. In aging, oxidative stress is a factor for
the reduced mitochondrial biogenesis. Oxidative stress is
considered as risk factor for insulin resistance for inhibition
of mitochondrial function. In high-fat diet models, H2O2
production is enhanced in mitochondria of human and rodent
skeletal muscles, and redox-buffering capacity is reduced in
the mitochondria19. When rodents were treated with a mito-
chondria-speciﬁc antioxidant or were genetically engineered to
overexpress mitochondrial catalase, H2O2 emission was atte-
nuated, and insulin sensitivity was preserved even in the face
of a high-fat diet19.
Mitochondrial dysfunction increases the risk for oxidative
stress, which in turn, activates various serine kinases (such as
JNK, IKK, PKC, et al.). These serine kinases contribute to
insulin resistance by phosphorylation of insulin receptor
substrate (IRS) proteins. In hepatocytes, palmitate accelerated
fatty acid b-oxidation and ROS generation, which inhibits
insulin signal transduction through activation of JNK20.
In addition, fatty acid metabolites such as DAG and long-
chain fatty acyl-CoA (LCFA-CoA) may contribute to insulin
resistance21,22. The intracellular accumulation of DAG acti-
vates PKCs, which increase serine phosphorylation of IRS
proteins in the inhibition of insulin signaling. Enhanced
oxidation of long-chain fatty acid in mitochondria is sufﬁcient
to reverse insulin resistance in liver and correct glucose
intolerance in db/db obese mice23. In this study, expression
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(CPT1mt) in liver increases hepatic mFAO capacity and
improves glucose tolerance in ob/ob mice. In the study, hepatic
steatosis was not affected in CPT1mt mice, indicating dis-
sociation between hepatic steatosis and insulin resistance.
A recent research suggests that genetic deletion of the AMPK
b1 subunit in mouse macrophages reduced fatty acid oxida-
tion, mitochondrial content, and increased risk for insulin
resistance. It suggests that increased fatty acid oxidation
in macrophages by AMPK activation may represent a new
therapeutic approach to the treatment of insulin resistance24.
Sedentary lifestyle and high-fat intake have deleterious
impact on muscle mitochondrial oxidative capacity, and
endurance exercise partly normalizes mitochondrial function
and prevents age-associated insulin resistance25. Lim et al.26
reported that insulin resistance is associated with impairment
of mitochondrial function. They demonstrated that chronic
exposure to atrazine (ATZ) could block the electron transfer
at Q site of electron transport chain and led to mitochondrial
dysfunction, including morphological disruption, decreased
activities of complexes I and III, and decreased oxygen
consumption rate in the liver and skeletal muscle. Conse-
quently, these resulted in insulin resistance in skeletal muscle
by reducing AKT phosphorylation at Thr308 and Ser473
upon insulin stimulation. These ﬁndings indicate that ATZ
may result in type 2 diabetes induced by impaired mitochon-
drial function.
Although a lot of articles suggest that mitochondrial
dysfunction contributes to the pathogenesis of insulin resis-
tance, more and more evidence suggests that inhibition of
mitochondria actually improves insulin sensitivity. Mitochon-
drial dysfunction hypothesis is mainly based on the associa-
tion studies, not cause/effect relationship studies. Recent
studies using pharmacological and transgenic approaches have
made a huge progress in the analysis of the cause/effect
relationship for mitochondrial dysfunction and insulin resis-
tance. The results consistently suggest that mitochondrial
dysfunction is a consequence, but not cause of insulin
resistance. Instead, mitochondrial over activation contributes
to insulin resistance in obese conditions7. Following two
points is supported by strong evidence: (I) mitochondrial
dysfunction is a protection mechanism against insulin resis-
tance; (II) mitochondrial inhibition is able to improve insulin
sensitivity.4. Mitochondrial inhibition as a strategy for insulin sensitization
Study of respiratory chain function in patients of type 2
diabetes suggests that mitochondrial dysfunction is not an
intrinsic defect, but rather a consequence of the impaired
insulin response27. In this study, the mitochondrial gene
transcripts encoding proteins in the electric transport chain
were expressed at higher levels in type 2 diabetic than in
nondiabetic subjects. Increased insulin at postprandial stage
caused an increase in mitochondrial ATP production rate in
nondiabetic but not in type 2 diabetic subjects. Increased
insulin reduced PGC-1, COX1, and citrate synthase expression
in type 2 diabetic patients, but not in nondiabetic subjects27. It
was reported that a reduction in oxidative phosphorylation in
the liver or muscle of mice did not trigger the onset of diabetes
but instead has the opposite effect, protecting mice againstboth diabetes and obesity28. The study suggests that the
changes in respiratory chain function in insulin-resistant
humans may be compensatory response in type 2 diabetes.
Mitochondrial dysfunction is not a cause of insulin resis-
tance6,7, but it may be a component of a ‘‘vicious cycle’’
exacerbating insulin resistance. Severe hyperglycemia can
reversibly inhibit mitochondrial respiration in skeletal muscle
cells29. Fatty acid also damages mitochondria functions30,31.
Insulin resistance will reduce mitochondrial biogenesis12. In
type 2 diabetes, hyperglycemia, hyperlipidimia and hyperinsu-
linemia together inhibits mitochondrial functions. In the
mechanism, ROS may play a role, which inhibits mitochon-
drial proteins through oxidative stress and activation of stress-
related signaling pathways.
In a time-course study, the relationship of insulin resistance
and mitochondrial dysfunction was investigated in mice on
a high-fat/high-sucrose diet32. Mice exhibited insulin resis-
tance and evidence of oxidative stress in muscle at 1 month
on the diet. Mitochondria impairment such as disrupted
mitochondrial biogenesis, loss of mitochondrial structural
integrity and respiratory functioning were found after pro-
longed exposure (41 month) to the diet32. These results show
that the mitochondrial dysfunction occurs after insulin
resistance.
A growing body of evidence has revealed the importance of
mitochondrial over activation in the pathogenesis of insulin
resistance7. Transient inhibition of mitochondrial function is
an approach in the improvement of insulin sensitivity. Many
insulin sensitizing medicines and small molecules can transi-
ently inhibit mitochondrial functions. Following pharmacolo-
gical and genetic evidence supports that mitochondrial over
activation contributes to insulin resistance and mitochondrial
inhibition improves insulin sensitivity.4.1. Pharmacological evidence
Pharmacological and genetic approaches have been used to
test the relationship of mitochondrial dysfunction and insulin
sensitivity. All of the clinically-approved medicines for insulin
sensitization are able to inhibit mitochondrial function. Ber-
berine, an herbal insulin sensitizer that is widely used in China,
represents a class of herbal drug in the treatment of type 2
diabetes. Berberine down-regulates the expression of genes
involved in lipogenesis and up-regulates those involved in
energy expenditure in adipose tissue and muscle33. Besides,
berberine treatment results in activation of AMPK, which
stimulates oxidation of glucose and fatty acids in mitochon-
dria. Berberine activates AMPK through inducing AMP/ATP
ratio by suppressing mitochondrial function34.
The mitochondrial inhibition is transient and reversible in
response to berberine. The mitochondrial function will be
enhanced by AMPK after disappearance of the berberine-
induced inhibition34. This study suggests that combination of
inhibition and stimulation of mitochondrial function may
contribute to improvement of insulin sensitivity. ATP deple-
tion in response to berberine is associated with inhibition of
gluconeogenesis and lipogenesis in the liver35. The study
suggests that inhibition of mitochondrial function in liver
may contribute to the therapeutic activities of berberine.
In another study, insulin sensitizing medicines including berbe-
rine, thiazolidinediones (TZDs), and metformin all inhibited
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likely the target of those drugs in the inhibition of mitochon-
drial function37–40, while resveratrol and quercetin inhibit the
ATP synthase 41.
Metformin is an effective anti-diabetic drug, which
decreases hyperglycemia through insulin-like and insulin-
sensitizing effects in liver and skeletal muscle cells. Metformin
does not directly stimulate AMPK. It activates AMPK by
inducing AMP/ATP ratio after inhibition of complex I of the
electron transport chain in mitochondria. Metformin also
enhances glucose utilization by uncoupling oxidative phos-
phorylation in isolated mitochondria42.
Thiazolidinediones (TZDs) are activators of PPAR and
function as insulin sensitizers. Troglitazone is the ﬁrst TZD-
derived insulin sensitizer. Troglitazone signiﬁcantly increased
phosphorylation of AMPK and ACC at 5 mM in 15 min
treatment. There was a transient increase in the AMP/ATP
ratio. In adipose tissue, TZD promotes mitochondrial biogen-
esis43,44. This activity may be related to AMPK activation.
Release of adiponectin by adipocytes and inhibition of
mitochondria may lead to AMPK activation. In addition,
TZD may enhance mitochondrial biogenesis through induc-
tion of gene expression, such as PGC-1, which has strong
activity in the mitochondrial biogenesis in vivo as shown in
transgenic mice.
Resveratrol, a polyphenolic compound extracted from
grape skins, has been demonstrated to increase the activity
of SIRT145 as well as AMPK46, which in turn activates PGC-
147. Resveratrol markedly attenuated weight gain in associa-
tion with increment of mitochondrial biogenesis in muscle and
adipose tissue in the high-fat-fed mice48. In parallel, the
resveratrol-treated mice show enhanced endurance capacity,
higher oxygen consumption as well as improved glucose
tolerance48. Resveratrol inhibits the mitochondrial ATP
synthase by binding to the subunit49, and leads to the
activation of AMPK. This mechanism may contribute to
insulin-sensitizing effect of resveratrol. The dose of resveratrol
used in mice is not feasible in humans, although the effects of
lower dose resveratrol was addressed in a human study50.
Resveratrol analogs, such as combretastatin A-4 (CA-4), can
function similarly as resveratrol and activate AMPK46.4.2. Genetic evidence
In genetic study, inhibition of mitochondrial function by gene
modiﬁcation leads to protection of insulin sensitivity51. Several
reports suggest mitochondrial hyperactivity and overload as
major cause of insulin resistance. This point has been demon-
strated in Asian Indian immigrants in the United States18 and
in animal models of diabetes and obesity28,52,53. Previous
genetic studies have shown that transient overexpression of
the ‘‘master regulator’’ of mitochondrial biogenesis, PGC-1,
increases mitochondrial content and insulin sensitivity in
skeletal muscle cells54,55. However, persistent overexpression
of PGC-1 in skeletal muscle induced systemic insulin resis-
tance by reducing GLUT4 expression56. In contrast, skeletal
muscle-restricted PGC-1 inactivation reduced mitochondrial
content and protected mice from insulin resistance57,58. These
mice show reduction in the mitochondrial biogenesis, low
activity in TCA cycle and a shift from oxidative to glycolytic
metabolism57,58.When PGC-1 is reduced by knockdown, the skeletal muscle
mitochondrial function was reduced in parallel with an
increase in glucose uptake and glucose tolerance59. Similarly
to the PGC-1 over expression mice, PPAR over-expressing
mice have an increase in mitochondrial function and a
decrease in insulin-induced glucose uptake in skeletal mus-
cle60. In these mice, insulin resistance is associated with
diminished AMPK activity.
Mitochondrial ﬂavoprotein apoptosis-inducing factor (AIF)
is required to maintain the integrity of the mitochondrial
respiratory apparatus, and this gene inactivation results in a
progressive disruption of mitochondrial respiratory function
with a long-term disruption in organ integrity61,62. Liver- and
muscle-speciﬁc AIF ablation induces OXPHOS deﬁciency in
mice, elevates glucose tolerance, reduces fat mass and
increases insulin sensitivity28. Interestingly, the absence of
PPAR in skeletal muscle results in down-regulation of mito-
chondrial biogenesis and function63. Moreover, these mice are
resistant to high-fat-induced weight gain and have higher
glucose tolerance even in the absence of exercise64.
A recent work on cardiolipin (CL) remodeling by ALCAT1
(a lyso-CL acyltransferase) suggests an alternative molecular
mechanism by which mitochondrial hyperactivity causes insu-
lin resistance51. ALCAT1 overexpression leads to CL deﬁ-
ciency and enrichment of docosahexaenoic acid (DHA)
content, which is known to increase mitochondrial membrane
potential, oxidative stress, and lipid peroxidation65,66. The
ATP production rate was stimulated by ALCAT1 overexpres-
sion and insulin sensitivity was reduced in the condition. In
opposite, insulin sensitivity was improved in muscle of knock-
out (ALCAT1/) mice. ALCAT1/ mice are protected from
diet-induced obesity and insulin resistance. In genetic obese
db/db mice, ATP production rate is signiﬁcantly higher in liver
mitochondria relative to the control mice. Besides, ATP
production rates were signiﬁcantly lower in isolated mitochon-
dria from liver and heart of ALCAT1/ mice. These data
support the notion that mitochondrial inhibition is able to
improve insulin sensitivity. Muscle-speciﬁc deletion of the
mitochondrial transcription factor Tfam does not induce
insulin resistance in mice, suggesting that mitochondrial
dysfunction in skeletal muscle is not a primary etiological
event in type 2 diabetes59.5. AMPK as a target for insulin sensitization
AMPK is a major cellular energy sensor and a master
regulator of metabolic homeostasis. It is a heterotrimeric
enzyme containing catalytic subunit and two regulatory
subunits. AMPK is activated by two distinct signals: a Ca2þ-
dependent pathway mediated by CaMKK and an AMP-
dependent pathway mediated by LKB167. AMPK serves as a
unique metabolic control node as it senses cellular energy
status through modulation of its activities via phosphorylation
and allosteric activation by AMP. A number of physiological
processes have been shown to stimulate AMPK, including
conditions that lead to alterations of the intracellular AMP/
ATP ratio, which are hypoxia, glucose deprivation; and
calcium concentration, as well as the action of various
hormones, cytokines, and adipokines. The AMPK activation
leads to the inhibition of energy-consuming biosynthetic
pathways (such as fatty acid synthesis in liver and adipocytes,
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muscle and insulin secretion from b-cells) and the activation of
ATP-producing catabolic pathways (such as fatty acid uptake
and oxidation in multiple tissue, glycolysis in heart and
mitochondrial biogenesis in muscle). AMPK can also mod-
ulate transcription of speciﬁc genes involved in energy meta-
bolism, thereby exerting long-term metabolic control.
Activation of AMPK in the liver and muscle is expected to
elicit a spectrum of beneﬁcial metabolic effects with the
potential to ameliorate the defects associated with insulin
resistance. Because of its favorable effects on energy metabo-
lism pathways, it is reasonable to consider AMPK as a
potential therapeutic target in the prevention and the treat-
ment of type 2 diabetes and insulin resistance.
There are a number of hormones and pharmacological
agents reported to activate AMPK in vivo upon treatment of
cells and tissues, such as metformin, TZDs, berberine, resver-
atrol, leptin, IL-6 and adiponectin. Changes in mitochondrial
coupling and cellular energy state could account for the
cellular AMPK activation. Metformin activates AMPK
through reducing ATP levels after uncoupling oxidative
phosphorylation in mitochondria in skeletal muscle cells;
TZDs can activate AMPK by a mechanism inducing adipo-
nectin expression in adipocytes68; adiponectin induces activa-
tion of AMPK in skeletal muscle and liver, increasing
phosphorylation of ACC and fatty acid oxidation, enhancing
glucose uptake and lactate production, and reducing glucose
levels in vivo69, IL-6 can rapidly and robustly increased
AMPK activity in myotubes, enhancing fatty acid oxidation
as well as basal and insulin-stimulated glucose uptake70.
AMPK activation in the liver and skeletal muscle generates
beneﬁcial metabolic effects in the diabetic patients. However,
the widespread AMPK activities make it hard to regulate the
kinase activity in a tissue-speciﬁc manner. We need to keep in
mind that AMPK activation could be beneﬁcial for diabetic
patients71,72.6. Mitochondrial PDH and insulin resistance
Pyruvate dehydrogenase (PDH) is an enzyme with multiunit
complex that catalyzes the conversion of pyruvate to acetyl-
CoA in the glucose catabolism pathway. PDH is localized
within the inner mitochondrial membrane, converting pyru-
vate to acetyl-CoA that is then oxidized in the trycarboxylic
acid (TCA) cycle for ATP production. PDH activity is also
required for fatty acid synthesis from glucose as acetyl-CoA is
the substrate in fatty acid synthesis. When PDH activity is
inhibited, glucose cannot be oxidized or converted into fatty
acids. PDH activity is tightly regulated by reversible serine
phosphorylation that is catalyzed by PDH kinase (PDK).
Phosphorylation of the E1 catalytic subunit by the kinase
inactivates the enzyme activity. The phosphorylation is cata-
lyzed by four speciﬁc PDH kinases: PDK1, PDK2, PDK3 and
PDK4. The activity of these kinases is enhanced by ATP,
NADH and acetyl-CoA and inhibited by ADP, NADþ and
CoASH73,74. The activity of PDH is also regulated by Mg2þ,
Ca2þ and insulin.
PDH activity is reduced in type 2 diabetes condition,
and the reduction is likely a result of insulin resistance.
Insulin induces PDH activity through de-phosphorylation to
enhance glucose utilization, which includes glycolysis, glucoseoxidation, and fatty acid synthesis. PDH is required for
glucose conversion into acetyl-CoA. Inhibition of PDH leads
to reduction in ATP generation and fatty acid synthesis from
glucose in most tissues. This point has been approved in
transgenic mice with PDH inactivation by a subunit knockout.
PDH inactivation in muscle, leads to heart hypertrophy in
mice and on chow diet, the KO mice die from heart failure
within a month after birth75. The inactivation in liver
completely blocks fatty acid synthesis from glucose in liver76.
However, glucose oxidation was not inhibited locally since
liver expresses pyruvate carboxylase, which sends pyruvate
into TCA cycle through oxaloacetate. In the liver-speciﬁc KO
mice, insulin sensitivity is enhanced and body weight is
reduced on chow diet76. A low PDH activity leads to a
decrease in glucose utilization and an increase in fatty acid
utilization in ATP production77. PDH activity is reduced in
diabetes or obesity conditions in various tissues in animals or
patients78,79. The reduced PDH activity is likely a result of
insulin resistance as insulin induces PDH function.
However, an increase in PDH activity is beneﬁcial in the
control of blood glucose in obese condition. PDH activity is
enhanced in PDK4 knockout mice, and is responsible for
hypoglycemia during starvation of the mice80. The hypogly-
cemia is a result of decreased gluconeogenesis from lack of
gluconeogenic substrate. PDH converts all pyruvates that
come from amino acids or glycerol into acetyl-CoA, which is
used in ATP production. However, this PDH activity protects
mice from hyperglycemia and insulin intolerance in mice on
HFD81. The KO mice have less weight gain on HFD, and this
may contribute to the improved glucose tolerance. These
studies suggest that an increase in PDH activity is beneﬁcial
in the control of blood glucose in obese condition. Current
literature on genetic studies suggests that inhibition and
activation of PDH activity both have beneﬁcial effects in the
control of insulin sensitivity in mice. More research is required
to determine if PDH is a therapeutic target in the improve-
ment of insulin sensitivity.7. Mitochondrial inhibitors
Many mitochondrial inhibitors have been reported in litera-
tures82. Some of them are known to increase insulin sensitivity.
These include berberine, metformin, TZDs, resveratrol, quer-
cetin, curcumin and estrogen. Other inhibitors remain to be
investigated for their activity in insulin sensitization. We list
examples in Table 1.8. Conclusions
Mitochondrial dysfunction is not likely a risk factor for insulin
resistance in type 2 diabetes. Instead, over activation of
mitochondria is a potential risk for insulin resistance.
A growing body of evidence has revealed the importance of
mitochondrial over activation in the pathogenesis of insulin
resistance. In obesity, substrate over-supply plus insulin
over-production is a mechanism for the mitochondria over-
activation. The mitochondria alteration leads to inhibition of
AMPK. Insulin resistance occurs after AMPK activity is
reduced (Fig. 3). These evidence-based views have advanced
our understanding of mechanism of insulin resistance.
Table 1 Mitochondrial inhibitors and their function.
Mitochondrial inhibitor Function
Berberine Inhibit mitochondrial respiration
Metformin Inhibit mitochondrial respiration, uncoupling oxidative phosphorylation
TZDs Inhibit respiratory chain complex I
Resveratrol Inhibit mitochondrial ATP synthase
Piceatannol Inhibit ATPase activity of mitochondrial ATP synthase
Diethylstilbestrol (DES) Inhibit proton translocation activities of mitochondria
Quercetin Inhibit ATPase activity of mitochondria
Genistein Inhibit ATP hydrolysis and ATP synthesis activities of mitochondrial ATP
synthase
Biochanin A Inhibit ATPase activity of mitochondria
Epicatechin gallate (ECG) Epigallocatechin gallate
(EGCG)
Inhibit ATP hydrolysis activity of ATP synthase
Curcumin Inhibit ATPase activity of mitochondria
Phloretin, theaﬂavin, tannic acid Inhibit ATPase activity of mitochondria
Estrogen Inhibit ATPase activity of mitochondria
Oligomycin Inhibit ATP synthase
Ossamycin Inhibit both ATPase and oxidative phosphorylation activities of mitochondrial
ATP synthase
Propranolol Inhibit mitochondrial ATPase activity
Atrazine Inhibit ATP synthesis activity of ATP synthase
Azide Inhibit ATPase activity of mitochondria
Figure 3 Mitochondrial inhibition as a new approach for insulin
sensitization. In obesity, mitochondria over-activation by sub-
strates and insulin leads to reduction in AMPK activity. Insulin
signaling activity is inhibited in the presence of AMPK inactiva-
tion. Inhibition of mitochondrial function is an alternative path-
way in AMPK activation.
Mitochondrial inhibitor as a new class of insulin sensitizer 347Inhibition of mitochondrial function is an approach in the
improvement of insulin sensitivity. Many insulin sensitizing
medicines and small molecules inhibit mitochondrial func-
tions. These activities of insulin sensitizing agents enforce our
proposal that mitochondrial inhibitors may represent a new
class of insulin sensitizer.Acknowledgements
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